Related Experiment Videos
[Pilot study of amiloride inhalation in children with cystic fibrosis]
1Kinderspital Salzburg.
Insights
Inhaled amiloride significantly increased sputum weight in cystic fibrosis (CF) patients by 57%, aiding mucus expectoration. However, it did not improve lung function in this short-term study.
Area of Science:
- Pulmonary Medicine
- Pediatric Respiratory Research
- Pharmacology
Background:
- Cystic Fibrosis (CF) impairs bronchial clearance due to altered sodium and chloride in secretions, reducing airway water.
- Amiloride, a sodium channel blocker, has shown potential in normalizing mucus sodium and improving mucociliary clearance.
Purpose of the Study:
- To evaluate the efficacy of inhaled amiloride in improving sputum characteristics and lung function in children with CF.
- To assess the safety and tolerability of aerosolized amiloride treatment.
Main Methods:
- A controlled, double-blind, crossover study involving nine pediatric CF patients.
- Twice-daily inhalation of amiloride (10(-3)M) or 0.9% saline for two-month periods.
- Assessment of sputum weight, consistency, and pulmonary function tests (FEV1, FVC, FEF50, FEF25, PEF).
Main Results:
- Inhaled amiloride increased mean daily sputum weight by 57% (from 11.75 g to 18.5 g).
- Some patients reported prolonged sputum expectoration and observed biphasic sputum consistency (solid/fluid).
- No significant improvements in pulmonary function tests or adverse effects were observed.
Conclusions:
- Inhaled amiloride effectively increases sputum weight and may alter sputum consistency in CF children.
- Short-term amiloride treatment did not yield significant pulmonary function improvements.
- Further research is warranted to explore the long-term effects of amiloride inhalation on CF disease progression.
Abstract:
Bronchial clearance is impaired in cystic fibrosis (CF). Respiratory secretions contain less sodium and chlorid, resulting in reduced airway water content. Aerosolized amiloride, a sodium transport blocker, was shown to normalize the amount of sodium in bronchial mucus, leading to an improvement in mucociliary clearance. In a controlled, double blind crossover study on nine CF children we tried to assess the efficacy of twice daily inhaled amiloride (10(-3)M) on sputum weight, consistency of sputum and lung function (FEF1, FVC, FEF50, FEF25, PEF). Each treatment period (amiloride versus 0.9% saline) lasted for two months. We could show that inhaled amiloride was able to increase mean sputum weight per day from 11.75 g (+/- 5.96) up to 18.5 g (+/- 10.34). This was equal to an increase of 57%. Some children felt that sputum expectoration lasted longer while using amiloride and that even for some hours after inhalation they expectorated a sputum-like fluid. We were able to detect, at least in some patients, that their sputum consisted of two parts, one showing more solid contents, the other more fluid-like contents. This was, however, not a consistent feature. No significant or clinical important differences were found for pulmonary function test data. There were no pulmonary or extra pulmonary side effects from treatment with amiloride. Further studies should be undertaken to assess the efficacy of longer lasting amiloride inhalation on the course of the disease in CF patients.